Cargando…
Small molecule inhibitors of RAS proteins with oncogenic mutations
RAS proteins control a number of essential cellular processes as molecular switches in the human body. Presumably due to their important signalling role, RAS proteins are among the most frequently mutated oncogenes in human cancers. Hence, numerous efforts were done to develop appropriate therapies...
Autores principales: | Orgován, Zoltán, Keserű, György M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680341/ https://www.ncbi.nlm.nih.gov/pubmed/32770300 http://dx.doi.org/10.1007/s10555-020-09911-9 |
Ejemplares similares
-
The role of water and protein flexibility in the structure-based virtual screening of allosteric GPCR modulators: an mGlu(5) receptor case study
por: Orgován, Zoltán, et al.
Publicado: (2019) -
Allosteric Molecular Switches in Metabotropic Glutamate Receptors
por: Orgován, Zoltán, et al.
Publicado: (2020) -
Prospective Development of Small Molecule Targets to Oncogenic Ras Proteins
por: Chandrashekar, Reena, et al.
Publicado: (2013) -
Structural impact of GTP binding on downstream KRAS signaling
por: Menyhárd, Dóra K., et al.
Publicado: (2020) -
Multi-targeting of K-Ras domains and mutations by peptide and small molecule inhibitors
por: Poorebrahim, Mansour, et al.
Publicado: (2022)